ArticleScientific reports2016
Chromatin interactions and candidate genes at ten prostate cancer risk loci.
Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- The landscape of GWAS validation; systematic review identifying 309 validated non-coding variants across 130 human diseases.BMC medical genomics · 2022Pooled it
- The Lipid Droplet-Associated Hydrolase Is Associated With Obesity and Adipose Tissue Inflammation in Children.Obesity (Silver Spring, Md.) · 2026Article
- A four-miRNA serum panel as a diagnostic biomarker for prostate cancer: an exploratory and validation study.Frontiers in oncology · 2026Article
- Multifaceted functions of transcription regulatory factor X6 (RFX6): from pancreatic development to cancer progression.Cancer cell international · 2025Review
- Evaluation of circulating plasma proteins in prostate cancer using mendelian randomization.Discover oncology · 2024Article
- Interpretation of the role of germline and somatic non-coding mutations in cancer: expression and chromatin conformation informed analysis.Clinical epigenetics · 2022Review
- Exploring the effects of genetic variation on gene regulation in cancer in the context of 3D genome structure.BMC genomic data · 2022Article
- Chromosome compartmentalization alterations in prostate cancer cell lines model disease progression.The Journal of cell biology · 2022Article
- Contribution of 3D genome topological domains to genetic risk of cancers: a genome-wide computational study.Human genomics · 2022Article
- Chromatin and Epigenetic Dysregulation of Prostate Cancer Development, Progression, and Therapeutic Response.Cancers · 2021Review
- CRISPRi screens reveal a DNA methylation-mediated 3D genome dependent causal mechanism in prostate cancer.Nature communications · 2021Article
- Article
- Chromatin Conformation in Development and Disease.Frontiers in cell and developmental biology · 2021Review
- Systematic analyses of genetic variants in chromatin interaction regions identified four novel lung cancer susceptibility loci.Journal of Cancer · 2020Article
- Emerging epigenomic landscapes of pancreatic cancer in the era of precision medicine.Nature communications · 2019Review
- Association of imputed prostate cancer transcriptome with disease risk reveals novel mechanisms.Nature communications · 2019Article
- Identification of Novel Susceptibility Loci and Genes for Prostate Cancer Risk: A Transcriptome-Wide Association Study in Over 140,000 European Descendants.Cancer research · 2019Article
- Dysregulated Transcriptional Control in Prostate Cancer.International journal of molecular sciences · 2019Review
- African KhoeSan ancestry linked to high-risk prostate cancer.BMC medical genomics · 2019Article
- Understanding the 3D genome: Emerging impacts on human disease.Seminars in cell & developmental biology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 2 countries.
Funding
Abstract
Genome-wide association studies have identified more than 100 common single nucleotide polymorphisms (SNPs) that are associated with prostate cancer risk. However, the vast majority of these SNPs lie in noncoding regions of the genome. To test whether these risk SNPs regulate their target genes through long-range chromatin interactions, we applied capture-based 3C sequencing technology to investigate possible cis-interactions at ten prostate cancer risk loci in six cell lines. We identified significant physical interactions between risk regions and their potential target genes including CAPG at 2p11.2, C2orf43 at 2p24.1, RFX6 at 6q22.1, NFASC at 1q32.1, MYC at 8q24.1 and AGAP7P at 10q11.23. Most of the interaction peaks were co-localized to regions of active histone modification and transcription factor binding sites. Expression quantitative trait locus (eQTL) analysis showed suggestive eQTL signals at rs1446669, rs699664 and rs1078004 for CAPG (p < 0.004), rs13394027 for C2orf43 (p = 2.25E-27), rs10993994 and rs4631830 for AGAP7P (p < 8.02E-5). Further analysis revealed an enhancer activity at genomic region surrounding rs4631830 which was expected to disrupt HOXB-like DNA binding affinity. This study identifies a set of candidate genes and their potential regulatory variants, and provides additional evidence showing the role of long-range chromatin interactions in prostate cancer etiology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.